Analytical Data
-
Gene name
Siglec-1/CD169
- Application
-
Alternative Names
CD169; SIGLEC1; Sialic Acid Binding Ig Like Lectin 1
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 95% as determined by SDS-PAGE.
-
Uniprot
Q9BZZ2
-
Expression Region
Gly34~Gly240
-
Molecular Weight
26kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Siglec-1, also known as CD169, is a member of the sialic acid-binding immunoglobulin-like lectin (Siglec) family, primarily expressed on macrophages and dendritic cells. It plays a crucial role in the immune system by facilitating the recognition and internalization of sialylated pathogens, thus influencing immune responses. The study of Siglec-1/CD169 has gained significant attention due to its potential applications in immunotherapy and vaccine development. Research indicates that this receptor not only participates in pathogen recognition but also modulates the interaction between immune cells and tumor microenvironments. Understanding the structural features and function of Siglec-1/CD169 through recombinant protein studies can provide insights into its role in immune regulation and its potential as a biomarker for certain diseases. Furthermore, the ability to produce recombinant Siglec-1/CD169 protein allows for the exploration of its binding affinities and therapeutic efficacy in various contexts, such as enhancing vaccine responses or targeting tumor cells. The ongoing research aims to unravel the complexities of Siglec-1/CD169 interactions and its implications in both innate and adaptive immunity, positioning it as a promising target for future therapeutic strategies. Through these investigations, scientists hope to harness the mechanisms of Siglec-1/CD169 to improve disease outcome and develop innovative approaches to combat infections and cancer.
